Genesis Molecular AI
156 employees
Biotech
Series B · $308.7M
Company details
Team Size156
IndustryBiotech
Funding
Total raised
$308.7M
Last stage
Series B
Investors
T. Rowe Price
Total raised
$308.7M
Last stage
Series B
Investors
Evan Feinberg
Evan Feinberg, PhD, co-founded Genesis Therapeutics and co-authored key peer-reviewed papers on deep learning technologies for drug discovery. He leads the company in pioneering AI for structure-driven drug design.
Vijay Pande
Vijay Pande, PhD, is the Stanford University professor whose lab Genesis Therapeutics spun out from, focusing on machine learning-powered simulations in chemistry, biology, and medicine.
No applications, no recruiter spam. Just the intro.
A few questions to make sure this role is the right shape for you. Two minutes.
I write the intro, send it to the founder, and handle the back-and-forth.
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.